CLO21-017: Hospitalization and Supportive Care Measure (SCM) Utilization in Patients With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC) in EMBRACA: Results From an Extended Follow-up Post-hoc Analysis

Authors:
Sara Hurvitz University of California, Los Angeles/Jonsson Comprehensive Cancer Center (UCLA/JCCC), Los Angeles, CA

Search for other papers by Sara Hurvitz in
Current site
Google Scholar
PubMed Close
 MD
,
Alexander Niyazov Pfizer, Inc., New York, NY

Search for other papers by Alexander Niyazov in
Current site
Google Scholar
PubMed Close
 PharmD, MPH
,
Ying Chen Pfizer, Inc., La Jolla, CA

Search for other papers by Ying Chen in
Current site
Google Scholar
PubMed Close
 PhD
, and
Hope S. Rugo University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Search for other papers by Hope S. Rugo in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 19: Issue 3.5
Online Publication Date:
17 Mar 2021
DOI:
https://doi.org/10.6004/jnccn.2020.7775
Restricted access

Funding: Pfizer Inc.

Corresponding Author: Alexander Niyazov, PharmD., MPH
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
Copyright:
Copyright © 2021 by the National Comprehensive Cancer Network 2021
Article Category:
Abstract
Print Publication Date:
20 Mar 2021
Online Publication Date:
17 Mar 2021

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1280 704 200
PDF Downloads 174 0 0
EPUB Downloads 0 0 0